BIG
OCUL icon

Brooklyn Investment Group’s Ocular Therapeutix OCUL Stock Holding History

Brooklyn Investment Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,238
Closed -$38.4K – 3389
2025
Q1 		$38.4K Buy
5,238
+3,155
+151% +$24.2K 0.01% 890
2024
Q4 		$17.8K Buy
+2,083
New +$20.3K 0.01% 783

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Brooklyn Investment Group's OCUL Position: Q2 2025 in Review

Brooklyn Investment Group sold out of Ocular Therapeutix (OCUL) in Q2 2025, closing a stake of 5,238 shares — an estimated $38.4K sold.

Brooklyn Investment Group first reported a position in OCUL in Q4 2024 and held it in 2 quarters. The position peaked at $38.4K in Q1 2025. 186 funds tracked by Wall St. Rank hold OCUL as of Q2 2025.

  • Brooklyn Investment Group reported no remaining Ocular Therapeutix position as of Q2 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 5,238 Ocular Therapeutix shares in Q2 2025, an estimated $38.4K.
  • Brooklyn Investment Group first reported a position in Ocular Therapeutix in Q4 2024 and held it in 2 quarters.
  • Brooklyn Investment Group's Ocular Therapeutix position peaked at $38.4K in Q1 2025.
  • 186 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2025.

Based on Brooklyn Investment Group's 13F filing for Q2 2025, filed 12 Aug 2025.